Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
APE Antibody (13B8E5C2), DyLight 755, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB100116IR
Description
APE Monoclonal specifically detects APE in Human, Mouse, Rat, Primate samples. It is validated for Western Blot, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Immunoblotting, Knockdown Validated.Specifications
| APE | |
| Monoclonal | |
| DyLight 755 | |
| 50mM Sodium Borate with 0.05% Sodium Azide | |
| APEX1 | |
| Purified human APE1 [Uniprot: P27695] | |
| 0.1 mL | |
| Autophagy, Base Excision Repair, Cancer, Core ESC Like Genes, DNA Repair, Stem Cell Markers | |
| Human, Mouse, Rat, Primate | |
| IgG2b |
| Western Blot, ELISA, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen), Immunoblot, KnockDown | |
| 13B8E5C2 | |
| Western Blot, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Immunoblotting, Knockdown Validated | |
| AP endonuclease 1, APE, APE1, APE-1, APEAPEX nuclease (multifunctional DNA repair enzyme), APENAP endonuclease class I, APEX deoxyribonuclease (apurinic or apyrimidinic), APEX nuclease, APEX nuclease (multifunctional DNA repair enzyme) 1, Apurinic-apyrimidinic endonuclease 1, APXAP lyase, DNA-(apurinic or apyrimidinic site) lyase, EC 3.1, EC 4.2.99.18, HAP1apurinic/apyrimidinic (abasic) endonuclease, multifunctional DNA repair enzyme, protein REF-1, redox factor 1, Redox factor-1, REF-1, REF1 apurinic/apyrimidinic exonuclease | |
| Mouse | |
| Protein G purified | |
| RUO | |
| Primary | |
| Store at 4°C in the dark. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction